JADE: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-masked, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of BI 1584862
Latest Information Update: 12 Feb 2025
Price :
$35 *
At a glance
- Drugs BI 1584862 (Primary)
- Indications Age-related macular degeneration; Dry macular degeneration
- Focus Therapeutic Use
- Acronyms JADE
- Sponsors Boehringer Ingelheim
- 10 Feb 2025 Status changed from not yet recruiting to recruiting.
- 16 Jan 2025 New trial record